LAS VEGAS, March 23, 2011 (GLOBE NEWSWIRE) -- Skinvisible, Inc. (OTCBB:SKVI) (OTCQB:SKVI) today announced the submission of an application for an Orphan Drug Product Designation for the Company's product formulated with Invisicare to treat Netherton Syndrome, a sub-type of ichthyosis disease. In conjunction with this application, Skinvisible has also filed a patent application with the US Patent Office.
